Medtronic PLC $MDT Stake Increased by Ieq Capital LLC

Ieq Capital LLC raised its position in Medtronic PLC (NYSE:MDT – Free Report) by 201.1% during the third quarter, Holdings Channel reports. The firm owned 304,001 shares of the medical technology company’s stock after purchasing an additional 203,045 shares during the period. Ieq Capital LLC’s holdings in Medtronic were worth $26,232,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Focus Advisor Solutions LLC raised its position in shares of Medtronic by 310.2% in the 3rd quarter. Focus Advisor Solutions LLC now owns 64,112 shares of the medical technology company’s stock worth $5,532,000 after acquiring an additional 48,483 shares in the last quarter. Checchi Capital Advisers LLC lifted its stake in shares of Medtronic by 32.4% in the 3rd quarter. Checchi Capital Advisers LLC now owns 5,418 shares of the medical technology company’s stock valued at $468,000 after purchasing an additional 1,327 shares during the period. Boston Partners boosted its position in shares of Medtronic by 22.9% during the 3rd quarter. Boston Partners now owns 4,672,722 shares of the medical technology company’s stock valued at $403,236,000 after purchasing an additional 870,606 shares in the last quarter. Independent Advisor Alliance boosted its position in shares of Medtronic by 11.7% during the 3rd quarter. Independent Advisor Alliance now owns 78,275 shares of the medical technology company’s stock valued at $7,039,000 after purchasing an additional 8,203 shares in the last quarter. Finally, OneAscent Financial Services LLC bought a new stake in shares of Medtronic during the 3rd quarter valued at about $301,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic News Summary

Here’s some of the latest news about MDT:

  • Positive Sentiment: BTIG Research raised its price target on Medtronic to $109 from $99 and reiterated a Buy rating, signaling confidence in further upside. BTIG Research rating and price target
  • Positive Sentiment: Analyst coverage points to growth potential from adoption of Medtronic’s Hugo surgical robot, international expansion and Neuroscience products. A separate report projects strong growth in connected health devices through 2032, a market that includes Medtronic. Medtronic growth prospects Connected health devices market report
  • Neutral Sentiment: A preview of Medtronic’s fiscal second-quarter results focused on expected metrics but did not report actual results, leaving investors awaiting the earnings update. Medtronic Q2 earnings preview

Wall Street Analysts Forecast Growth

MDT has been the topic of a number of research reports. BTIG Research boosted their target price on shares of Medtronic from $99.00 to $109.00 and gave the company a “buy” rating in a research report on Thursday. Bank of America increased their target price on Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, September 2nd. Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a report on Monday. Needham & Company LLC reiterated a “buy” rating on shares of Medtronic in a report on Thursday, September 17th. Finally, Wells Fargo & Company raised their target price on Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a report on Wednesday, September 2nd. Eighteen analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $104.17.

Get Our Latest Stock Analysis on Medtronic

Medtronic Stock Down 0.1%

MDT stock opened at $100.57 on Friday. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $128.64 billion, a PE ratio of 24.77, a PEG ratio of 2.36 and a beta of 0.56. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The stock has a 50-day simple moving average of $94.44 and a two-hundred day simple moving average of $88.47.

Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion for the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The company’s revenue was up 13.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities analysts predict that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Insider Activity

In other news, EVP Harry Kiil sold 1,483 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the transaction, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. This represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael Marinaro sold 10,420 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the transaction, the executive vice president owned 105,916 shares in the company, valued at $10,167,936. This represents a 8.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 61,903 shares of company stock worth $5,889,203 in the last three months. Corporate insiders own 0.27% of the company’s stock.

About Medtronic

(Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Featured Stories

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.